How Long Can You Live With Prostate Cancer?

Most men diagnosed with prostate cancer today will not die from it. For those with low-grade tumors, life expectancy is essentially the same as someone without the disease, and ten-year cancer-specific survival sits near 100%. But the range is enormous: men with the most aggressive forms that have spread and stopped responding to hormone therapy face a median survival measured in months, not decades. The answer depends almost entirely on the grade and stage at diagnosis, the biology of the individual tumor, and what treatments are available.

Low-Grade Prostate Cancer Often Does Not Shorten Life

Prostate cancer is graded by how abnormal the cells look under a microscope, and the lowest-grade tumors behave so slowly that many will never cause symptoms. A long-term study found that men with the lowest-grade tumors (Gleason score 2 to 4) had survival that was statistically no different from the general population, even after a mean follow-up of more than 15 years.¹ That means, for this group, the cancer did not meaningfully change how long they lived.

The modern approach for these slow-growing cancers is active surveillance: regular monitoring with blood tests and biopsies rather than immediate surgery or radiation. Data from Memorial Sloan Kettering on over 2,600 men with the lowest-risk cancers showed a ten-year overall survival of about 94%, and only a single patient in the entire cohort died of prostate cancer. Ten-year cancer-specific survival was essentially 100%.² A separate population-based study confirmed these numbers, reporting ten-year cancer-specific survival above 98% and metastasis-free survival above 94% among men on active surveillance.³

For men in this category, the honest answer to “how long can you live” is: probably as long as you would have lived without the diagnosis. The cancer exists, but it is unlikely to be the thing that kills you. The small percentage who do eventually need treatment typically get it after the cancer shows signs of becoming more aggressive on a follow-up biopsy, at which point curative options are still on the table.

Intermediate and High-Grade Tumors Shorten Life, but by How Much Varies

Once you move beyond the lowest-grade cancers, the picture changes. Tumors graded as Gleason 5 to 7 carry a real but moderate cost: the same long-term study that found no difference for low-grade cancers estimated that men with these intermediate tumors lost roughly four to five years of life expectancy compared to the general population.¹ For high-grade cancers (Gleason 8 to 10), the estimated loss was six to eight years.

Those numbers come from a study of men managed conservatively, meaning many did not receive aggressive treatment. With modern surgery or radiation, outcomes for intermediate and high-grade disease are substantially better than watchful waiting alone. A study comparing treatment approaches for high-grade tumors found that men who underwent radical prostatectomy had a median overall survival of about ten years, compared with roughly seven years for radiation and five years for conservative management. The risk of dying specifically from the cancer was about 68% lower with surgery than with conservative care.⁴

Disease-specific survival data by grade paints a clearer picture. One analysis reported mean cancer-specific survival of about 20 years for the lowest Gleason scores (4-5), dropping to around 16 years for Gleason 6, ten years for Gleason 7, and five years for Gleason 8 to 10.⁵ Among the very highest grade tumors (Gleason 9 and 10), a nationwide population study found that the risk of dying from prostate cancer within ten years ranged from about 45% to 66%, depending on the exact pattern of the cells.⁶

Advanced Disease and Castration Resistance

Prostate cancer that has spread to distant sites or that no longer responds to hormone-lowering treatments enters a different category. The standard first-line therapy for advanced prostate cancer is androgen deprivation therapy (ADT), which cuts off the testosterone that fuels tumor growth. For many men, this works for years. But eventually the cancer can adapt and begin growing again despite very low testosterone levels, a state called castration-resistant prostate cancer (CRPC).

Once castration resistance develops, survival depends on whether the cancer has already spread. A Swedish population-based study found that men who reached CRPC without visible metastases at original diagnosis had a median survival of about 23 months from the onset of castration resistance, while those who had metastases at their initial diagnosis survived a median of about 13 months.⁷ A larger real-world cohort of over 4,000 CRPC patients found a median overall survival of just under two years regardless of metastasis status.⁸

For men with metastatic castration-resistant prostate cancer specifically, a study of the US Medicare population found a median survival of roughly 26 months from diagnosis of that stage.⁹ These are sobering numbers, but they represent medians: some men live considerably longer, particularly with access to newer treatment combinations.

What Makes Some Cancers More Dangerous Than Others

Grade alone does not tell the full story. Two men with the same Gleason score can have very different trajectories, and several biological markers help predict who will do well and who will not.

One of the most powerful predictors after initial treatment is how fast PSA levels rise if the cancer comes back. PSA doubling time, the number of months it takes for PSA to double after a recurrence, is strongly linked to the risk of dying from prostate cancer. In one study, men whose PSA doubled in less than three months after surgery had roughly a 20-fold higher risk of dying from their cancer compared to men with slower-rising PSA.¹⁰ A separate analysis found that the five-year risk of dying from prostate cancer after a recurrence was about 50% for men whose PSA doubled in 12 months or less, compared to roughly 10% for men with slower doubling.¹¹ Rapidly rising PSA after treatment is a red flag that often prompts more aggressive salvage therapy.

Genetics also play a role. Men who carry mutations in the BRCA2 gene, better known for its association with breast cancer, are far more likely to develop aggressive prostate tumors. In a screening study, 96% of BRCA2 carriers had high-grade disease at diagnosis compared with about half of non-carriers. Twelve-year survival was markedly worse for the carriers: about 62% compared with 94% for men without the mutation. Even after accounting for the higher grade, BRCA2 carriers still had roughly three and a half times the risk of dying from their cancer.¹² Research has also confirmed that both BRCA1 and BRCA2 mutations are associated with a higher probability of the cancer spreading to lymph nodes and distant sites.¹³ Men with a family history of BRCA-related cancers may benefit from earlier and more aggressive screening.

How Treatment Choice Affects Long-Term Outcomes

For cancers that stay within the prostate, the three main approaches are active surveillance, surgery (radical prostatectomy), and radiation therapy (external beam or brachytherapy). Choosing among them involves weighing survival against quality of life, and the data suggest that cancer-specific survival is quite similar between surgery and radiation for localized disease. A population-based study using matched comparisons found no significant difference in cancer-specific survival between the two treatments, though surgery was associated with modestly better overall survival, likely because surgical patients tend to be healthier to begin with.¹⁴

Where the treatments differ more clearly is in their side effects. A systematic review found that active surveillance had the least impact on cancer-related quality of life over six years of follow-up. Surgery tended to cause more problems with urinary control and sexual function compared to both surveillance and radiation. Radiation, on the other hand, was more likely to affect bowel function.¹⁵ A large New England Journal of Medicine study confirmed this pattern: each treatment came with its own distinct set of quality-of-life trade-offs related to urinary, sexual, bowel, and hormonal function.¹⁶

Encouragingly, general quality of life tends to recover well. A study comparing prostate cancer patients under 75 with age-matched controls found that overall quality-of-life scores were high and did not differ between the two groups three years after diagnosis.¹⁷ The specific functional domains (sexual, urinary) remain affected, but overall well-being is often preserved.

The Risks That Are Not the Cancer Itself

A surprisingly large number of men with prostate cancer die of something other than their cancer. One study of deceased prostate cancer patients found that about 46% died from other causes, with cardiovascular disease being a leading contributor.¹⁸ Among elderly men specifically, only about 39% of deaths were attributable to the prostate cancer itself.¹⁹ This is part of why active surveillance is a sound choice for low-risk disease: treating a cancer that would never have threatened your life exposes you to side effects without extending it.

Hormone therapy itself carries cardiovascular risks. Because ADT lowers testosterone so dramatically, it affects metabolism, body composition, and cholesterol in ways that increase the likelihood of heart attacks, strokes, and other cardiovascular events. Cardiovascular disease is already the second leading cause of death in men with prostate cancer, and an estimated two-thirds of men with the disease are at elevated cardiovascular risk.²⁰ This is why doctors increasingly monitor heart health as part of prostate cancer care, especially in men on long-term ADT.

Radiation therapy carries a small but real risk of causing a second cancer in nearby organs. A study of over 140,000 men found that those treated with radiation had a roughly 24% higher risk of developing a second primary cancer within five years compared to men who had surgery, and the risk climbed to about 50–60% higher at ten to fifteen years.²¹ Bladder and lung cancers were the sites with the strongest association.²² The absolute numbers remain small, and for men with aggressive cancers, the survival benefit of radiation far outweighs this risk. But it is worth factoring in for men with low-risk disease and long remaining life expectancies, where the downstream risk has decades to accumulate.

Racial Disparities in Survival

Prostate cancer has the widest racial disparities of any cancer.²³ Black men are diagnosed more often, at younger ages, and with more aggressive disease, and they face higher mortality rates. A modeling study estimated that among men who have undiagnosed prostate cancer, Black men have a 44–75% higher risk of the cancer spreading before it is detected compared with the general population.²⁴

The reasons behind these disparities are a mix of biology and access. Black men are more likely to develop preclinical disease in the first place, and the disease appears to be biologically more prone to progression. But structural barriers compound this: Black men have less access to treatment and experience longer delays between diagnosis and treatment initiation.²⁵ Studies consistently show that when Black men receive the same quality of care as white men, the survival gap narrows considerably. The disparity is not destiny, but it requires active attention from patients and their health systems.

When Prostate Cancer Strikes Younger Men

Prostate cancer is overwhelmingly a disease of older men, with a median age at diagnosis around 66. But it does occur in younger men, and when it does, the picture can be counterintuitive. Men diagnosed between ages 40 and 80 have five-year relative survival rates between 95% and 100%. For the rare cases diagnosed before age 35, that number drops dramatically, to around 30–80% depending on the exact age bracket, largely because younger men are much more likely to already have metastatic disease when they are finally diagnosed.²⁶ Younger men are simply not being screened, so by the time symptoms force a diagnosis, the cancer has often progressed further.

Among younger men who do get treated with surgery, outcomes are generally good. A study of men under 55 who underwent radical prostatectomy found that the majority had favorable pathology, and there were no differences in prostate cancer-specific death rates between younger and older surgical patients. Five- and ten-year overall survival were actually slightly better for men aged 45 to 54 than for older men, likely reflecting their overall better health.²⁷ The takeaway is that young men with prostate cancer are not inherently worse off. The danger is late detection.

Exercise and Lifestyle After Diagnosis

There is growing evidence that what you do after a prostate cancer diagnosis affects how long you live. In the Health Professionals Follow-Up Study, men who engaged in at least three hours per week of vigorous physical activity after diagnosis had a 61% lower risk of dying from prostate cancer compared to men who did less than one hour per week.²⁸ That is a large effect for a behavioral factor, and it persisted after adjusting for other health characteristics. Physical activity was also linked to lower all-cause mortality, meaning it reduced the risk of dying from any cause, not just cancer.

Dietary interventions are less clear-cut. A systematic review of nutritional and physical activity interventions found some small trials showing benefits from supplements containing combinations like pomegranate, green tea, broccoli extract, and turmeric, or from soy and lycopene. But the evidence remains thin and inconsistent enough that no specific dietary protocol can be confidently recommended for extending survival.²⁹ Exercise, by contrast, has a much stronger and more consistent evidence base behind it.

Newer Treatments for the Most Advanced Cases

For men with metastatic castration-resistant disease, which used to be a near-terminal diagnosis, the treatment landscape has been changing. One of the most notable advances is a radioactive drug called lutetium-177-PSMA-617, which targets a protein on the surface of prostate cancer cells and delivers radiation directly to the tumor. The landmark VISION trial found that adding this therapy to standard care extended median overall survival from about 11 months to roughly 15 months and more than doubled the time before the cancer progressed on imaging.³⁰ Four extra months may not sound like much, but for a cancer that had few options left, it represents a meaningful shift.

Subsequent analyses have confirmed these findings. A meta-analysis in JAMA Network Open replicated the survival benefit, and real-world studies of patients who received the therapy, including some who had already been treated with radium-223, reported median overall survival of about 13 months from the start of lutetium treatment.³¹ These are among the first targeted radionuclide therapies to show a clear survival benefit in prostate cancer, and they are now being tested earlier in the disease course, where results could be even more striking.

Global Differences in Prostate Cancer Survival

Where you live matters. Countries with high healthcare spending tend to have much better prostate cancer survival, largely because of earlier detection and wider access to treatment. But a study of global trends found something troubling: even among wealthy nations, improvements in the ratio of prostate cancer deaths to new diagnoses have stalled in recent years.³² Meanwhile, in low-income countries, death rates have actually been rising. Between 1990 and 2019, age-standardized mortality increased over 14% in low-income nations even as it fell in wealthy ones.³³ The gap is widening, not closing, making prostate cancer survival increasingly a question of geography and resources.